Phase 1 Relapsed Non Hodgkin Lymphoma Clinical Trials

2 recruitingPhase 1

What is a Phase 1 trial?

Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.

Showing 1–2 of 2 trials

Recruiting

Phase 1Phase 2

Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)

Relapsed Pediatric ALLRelapsed Non Hodgkin LymphomaRelapsed Adult ALL

University of Alberta63 enrolled6 locationsNCT03938987

Recruiting

Phase 1

CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

Lymphoma, Non-HodgkinRefractory B-Cell Non-Hodgkin LymphomaRelapsed Non Hodgkin Lymphoma

Caribou Biosciences, Inc.72 enrolled38 locationsNCT04637763